Thiazole Crystal Forms for Herpes Antiviral Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for herpes simplex virus infections, such as those using zidovudine, ganciclovir, acyclovir, and foscarnet, have significant side effects and limited efficacy due to DNA replication damage in host cells and viral resistance, necessitating the development of more effective antiviral agents.
Innovation Solution
A novel thiazole compound in specific crystal forms (A and B) with defined X-ray powder diffraction patterns, differential scanning calorimetry curves, and thermogravimetric analysis profiles, demonstrating stability and antiviral activity against herpes simplex virus, offering improved safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral treatments (zidovudine, ganciclovir, acyclovir, foscarnet) are used to treat herpes simplex virus infections, then antiviral effect is achieved, but side effects increase and viral resistance develops
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of thiazole compounds to create novel derivatives with improved antiviral activity. The specific structural modifications (introducing various substituents at different positions of the thiazole ring) change the pharmacological parameters of the compound, resulting in better efficacy and reduced side effects compared to conventional antiviral agents
Solution Approach 2:
The patent employs composite material principles by creating complex thiazole compounds with multiple functional groups and substituents. These composite molecular structures combine different chemical moieties that work synergistically to enhance antiviral activity while reducing toxicity and preventing resistance development
2Reliability
If existing antiviral drugs are administered to achieve therapeutic effect, then viral infection is suppressed, but DNA replication of host cells is damaged
Solution Approach 1:
The patent applies local quality by designing thiazole compounds with specific functional groups that target viral enzymes selectively. The molecular structure is optimized to interact preferentially with viral DNA polymerase or other viral targets, leaving host cell DNA replication machinery unaffected, thus achieving selective antiviral activity with reduced host toxicity
Data Source
AI summary
Disclosed by the present invention are a crystal form A of a compound represented by formula (I), a compound represented by formula (II) and a crystal form B thereof, as well as an application of the crystal form A of the compound represented by formula (I), the compound represented by formula (II) and the crystal form B thereof in the preparation of a drug for the treatment diseases associated with the herpes simplex virus.